Navigation Links
CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
Date:8/20/2008

matoid Arthritis vaccine."

About Multikine:

In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007.

CEL-SCI is currently building a manufacturing facility for Multikine close to Baltimore, MD. Upon completion of the facility in the 3rd quarter of 2008, CEL-SCI will commence the Phase III clinical trial. Multikine appears to be the first non-toxic cancer drug.

Multikine, a patented defined mixture of naturally derived cytokines, is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS". Immune SIMULATORS simulate the way our natural immune system acts in defending us against cancer. As opposed to other immunotherapies which are designed to target a single or limited number of specific antigens or molecules, Immune SIMULATORS are multi-targeted; they simultaneously cause a direct and targeted killing of the specific tumor cells and they activate the immune system to produce a stronger anti-tumor attack on multiple fronts.

Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received chemotherapy and/or radiation therapy, which can limit th
'/>"/>

SOURCE CEL-SCI CORPORATION
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. CEL-SCI to Present at the Noble Financial Conference
4. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
5. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
6. MannKind Corporation Reports Second Quarter Financial Results
7. Genaera Corporation Announces Second Quarter Financial Results
8. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
9. Pharmos Corporation Reports 2008 Second Quarter Results
10. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
11. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... San Diego, CA (PRWEB) October 30, 2014 ... company announced today that they have manually curated public ... Pharma and non profit customers. the data is ... BioSciences manually curates and unifies public and internal data ... more value and knowledge out of the data that ...
(Date:10/30/2014)... Erlanger, Kentucky (PRWEB) October 30, 2014 Avure ... of the 525L, the newest member of its fleet of ... to be reaching an anniversary as we return to PackExpo ... a year ago in Las Vegas,” said Jeff Williams, CEO ... extremely well, and we’re pleased to be meeting the challenges ...
(Date:10/30/2014)... , Oct. 30, 2014  Regado Biosciences, Inc. (Nasdaq: ... hold a conference call and live audio webcast on ... discuss its third quarter 2014 financial results. ... by dialing (888) 347-1165 for domestic callers or (412) ... webcast live under the investor relations section of the ...
(Date:10/27/2014)... 2014 The new research report, ... & Medium), Sub-type (Primary & Secondary), and End-User ... Transportation & Power Generation) - Trends and Forecasts ... with analysis and forecasting of the market size. ... with 52 Figures spread through 146 Pages and ...
Breaking Biology Technology:Rancho BioSciences Manually Curated TCGA Data Sets Available 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Regado Biosciences to Provide Third Quarter 2014 Financial Results 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
... , 3Q09 Corporate Highlights: ... Astellas Pharma Europe Ltd. Made significant progress in ... Sales; Senior Director, Marketing; and Director, Commercial Operations Appointed ... chairman , Upcoming 2009 Milestones: ...
... . . . Fuel economy ratings for ... the www.fueleconomy.gov web site, which Oak Ridge National ... and the U.S. Environmental Protection Agency. Nine of the top ... electrics, led by the Toyota Prius (51 MPG city; 48 ...
... 5 ThermoGenesis Corp. (Nasdaq: KOOL ), a leading ... cells, today reported results for the first quarter of fiscal ... Company reported revenues of $5.2 million, a 15 percent increase ... year ago. The Company said the key contributors to the ...
Cached Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8
(Date:10/30/2014)... professor has received a $1.04 million grant from ... tissue and reduce osteoarthritis using a patient,s own ... made of biodegradable polymers., Liping Tang, a bioengineering ... said the research is primarily focused on helping ... "We,ve found that if we inject microscaffolding that ...
(Date:10/30/2014)... available in German . ... our fellow humans to behave socially? This is one ... game theory. Previous studies assumed that it is almost ... from the Max Planck Institute for Evolutionary Biology have ... influence on the cooperative behaviour of others. However, the ...
(Date:10/30/2014)... Bacteria in the gastrointestinal tract fulfill many vital ... same bacteria can induce strong inflammatory responses by ... and enter the bloodstream. , Although acute inflammation ... chronic or systemic inflammation is linked to numerous ... involvement of inflammatory processes in the development of ...
Breaking Biology News(10 mins):UTA researcher uses microscaffolding injections to mend cartilage, prevent osteoarthritis 2Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4Breakdown in gut barriers to bacteria may promote inflammation and craving in alcoholics 2
... population in Canada, but the statistics are even more ... a study published recently in the American Journal of ... to 65 per cent of Cree preschoolers in northern ... Willows, a community nutritionist at the University of Alberta, ...
... potential has so far gone largely untapped. But new research ... shows that adult stem cells taken from skin can be ... The findings are reported in the Feb. 12 online edition ... Embryonic stem cells have received the most press for their ...
... the April 15th issue of Genes & Development, Dr. ... the minimal DNA structure sufficient to activate the ATR-mediated ... about these results," says Dr. Cimprich. "The ability to ... activating structure in an experimental system will enable us ...
Cached Biology News:Scientists clone mice from adult skin stem cells 2Scientists clone mice from adult skin stem cells 3
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... Cytokeratin TYPE II Reacts with most ... epidermal cell keratin of 86 and 58kD ... Broad keratin reactivity is found on human ... Immunogen: Human epidermal cells ...
BD BioCoat Fibronectin 150 mm Culture Dishes...
... new product number, created to easily match ... yet, please order under the old Sigma-Aldrich ... assistance. ID clarifier: tissue-culture treated ... cm 2 D H 245 ...
Biology Products: